Leal Therapeutics, Inc.

About Leal Therapeutics, Inc.

Leal Therapeutics is focused on pioneering neuro-metabolic therapies for high-need central nervous system (CNS) disorders. The company develops novel precision CNS therapeutics targeting key pathogenic pathways.

Products & Services

LTX-001:A small molecule targeting GLS1 to address excessive CNS glutamate, indicated for Schizophrenia, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and ALS.

LTX-002:An Antisense Oligonucleotide (ASO) targeting SPTLC1 to address excessive CNS sphingolipids, indicated for ALS.

LTX-003, LTX-004:ASOs targeting multiple pathways, indicated for Alzheimer's Disease.

Specialties

Neuro-metabolic therapies CNS disorders Precision CNS therapeutics Lipid biology Glutamate biology Small molecule development Antisense Oligonucleotide (ASO) therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 30000000 MR: - FA: $30 million FAN: 30000000	D: 2025-08-27 FD: 2025-08-27	7 investors
2	RT: Financing Round T: - FT: Financing Round	A: 45000000 MR: - FA: $45 million FAN: 45000000	D: 2024-10-30 FD: 2024-10-30	6 investors

Series A Latest

2025-08-27

$30.0M

7 investors (Pro only)

Financing Round 2024-10-30

$45.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Asa Abeliovich

CEO and Founder

E

Eduardo Paredes

Senior VP, CMC

H

Herve Rhinn

Senior Vice President of Discovery & Bioinformatics

L

Laura D. Heckman

Senior Vice President of Translational Sciences

L

Lawrence Severt

Vice President, Clinical Development

H

Hong Jiang

Vice President, Analytical Science and Development

View 10 more team members with Pro

Unlock Full Team Directory

Recent News